RZLT rezolutebio.com Earnings growth forecast for next year

Rezolute, Inc. (RZLT) aims to secure a monopoly position in the treatment of rare endocrine pathologies through its drug RZ358. A shift in the consensus earnings per share forecast confirms these expectations, with the value 27.60 describing the current level. The company is implementing eco-friendly chemical disposal in its laboratories, and its market capitalization depends on clinical trial outcomes, rendering the asset decoupled from macroeconomic trends.

Rezolute Corp (RZLT): Expected net earnings per share growth next year from 07/04/2022 to 11/14/2026

RZLT (rezolutebio.com): analytical breakdowns and indicator data

- share price and consensus valuation forecast:

Stock Price Rezolute Corp|RZLT - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Rezolute|RZLT - Total Company Value

- book capitalization indicators:

Net Assets per Single Share Rezolute|RZLT - Total Stockholders' Equity|Market Value to Book Value Ratio rezolutebio.com|RZLT - Aggregate Company Assets

- debt and solvency information:

- net income and valuation ratios data:

RZLT - Company Net Income|Future Profit Rezolute, Inc.|RZLT - Market Cap to Net Income|Future Price to Earnings Rezolute, Inc.|RZLT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rezolute|RZLT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Rezolute|RZLT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com|RZLT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Rezolute, Inc.

- total revenue and sales volume data:

RZLT - Company Total Revenue|Company Future Sales Volume Rezolute Corp|RZLT - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Rezolute

Initial company analysis:RZLT, Rezolute Corp

This indicator measures the expected earnings per share (EPS) dynamics, allowing investors to assess the market consensus regarding future business performance and adjust the asset's risk profile in a timely manner. When analyzing the projected net income per share growth for year n+1, it should be noted that for Rezolute, Inc. (RZLT), the potential for monetizing endocrinology patents depends directly on FDA approval, making current forecasts an indicator of market confidence in the success of clinical trials.

Analysis of competing companies